Hormone sensitive protocol for metastatic prostate cancer, an update

被引：0

作者：

Ossorioa, J. L. Alvarez ^{[1
,2
,3
]}

Aliagac, M. Rodrigo ^{[4
]}

Antolind, A. Rodriguez ^{[5
]}

Urzaize, M. Unda ^{[6
]}

Callejaf, M. A.

Ruizg, M. de la Cruz ^{[7
]}

Quilezh, J. Blas ^{[8
]}

Millani, I. R. Hernandez ^{[9
]}

Zalabardoj, D. Sanchez ^{[10
]}

Olmo, J. M. Cozar

机构：

[1] Hosp Univ Puerta Mar, Serv Urol, Cadiz, Spain

[2] Asociac Espanola Urol AEU, Madrid, Spain

[3] Fdn Invest Urol FIU, Madrid, Spain

[4] Hosp Gen Univ Castellon, Serv Urol, Castellon de La Plana, Spain

[5] Hosp Univ 12 Octubre, Serv Urol, Madrid, Spain

[6] Hosp Univ Basurto, Serv Urol, Bilbao, Vizcaya, Spain

[7] Hosp Son Espases, Serv Urol, Palma De Mallorca, Baleares, Spain

[8] Hosp Univ Virgen Salud, Complejo Hosp Toledo, Toledo, Spain

[9] Hosp Univ Albacete, Albacete, Spain

[10] Hosp Reina Sofia, Navarra, Spain

来源：

ACTAS UROLOGICAS ESPANOLAS | 2023年 / 47卷 / 04期

关键词：

Androgen deprivation therapy; Clinical follow-up; Hormone sensitive metastatic prostate cancer; Treatment; ANDROGEN DEPRIVATION THERAPY;

D O I：

10.1016/j.acuro.2022.09.003

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

To review and update last protocols in hormone sensitive metastatic prostate cancer for improving clinical management in routine. Evidence analysis available about recent updates protocols in hormone sensitive metastatic prostate cancer according to expert panel of clini-cians about this field. A nominal consensus group for unify and improve the recommendations to the management of sensitive metastatic prostate cancer patients is currently needed. This document unifies and improve the management of patients with hormone sensitive metastatic prostate cancer, with a methodology that combines data quantitative and qualitative and based on the participation of a broad scientific committee appointed by the Spanish Association of Urology. (c) 2022 AEU. Published by Elsevier Espan similar to a, S.L.U. All rights reserved.

引用

页码：244 / 249

页数：6

共 50 条

[31] Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy
Chakrabarti, Deep
Parker, Chris C.
EUROPEAN UROLOGY, 2024, 86 (01) : 18 - 19
[32] Prostate radiotherapy for metastatic hormone sensitive prostate cancer-myth or reality?
Onal, Cem
TRANSLATIONAL CANCER RESEARCH, 2019, 8 (07) : 2508 - 2509
[33] Xtandi® Extensive care in hormone-sensitive metastatic prostate cancer
不详
ACTUALITES PHARMACEUTIQUES, 2022, 61 (616): : 9 - 9
[34] How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Dabkara, Deepak
Mondal, Debapriya
Ghosh, Joydeep
Biswas, Bivas
Ganguly, Sandip
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (01) : 100 - 107
[35] Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Mathieu, Romain
Shariat, Shahrokh F.
EUROPEAN UROLOGY, 2016, 69 (04) : 755 - 756
[36] Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
Chen, Kenneth
McVey, Aoife
Kasivisvanathan, Veeru
Jenjitranant, Pocharapong
Azad, Arun
Murphy, Declan G.
EUROPEAN UROLOGY, 2022, 82 (01) : 146 - 147
[37] Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Wala, Jeremiah
Nguyen, Paul
Pomerantz, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3584 - +
[38] SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
Omrcen, Tomislav
ACTA CLINICA CROATICA, 2022, 61 : 81 - 85
[39] Prescription Medications and Overall Survival in Metastatic Hormone Sensitive Prostate Cancer
Pickett, Carley
Karunanandaa, Krishny
Stackable, Kaitlin
Eaton Jr, Daniel B.
Tohmasi, Steven
Gopukumar, Deepika
Puri, Varun
Schoen, Martin W.
ANTICANCER RESEARCH, 2024, 44 (08) : 3443 - 3449
[40] Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Arnold Lee
Targeted Oncology, 2023, 18 (5) : 801 - 801

← 1 2 3 4 5 →